Artiva Biotherapeutics Q2 FY26 net loss widens to $25.01 million; R&D expenses rise to $21.93 million
ARTV•Q2 results and spending
Artiva Biotherapeutics posted a Q2 net loss of $25.01 million, widening from $21.25 million a year earlier.
Research and development spending rose to $21.93 million from $17.86 million, while general and administrative expense was little changed at $4.97 million.
Cash position and clinical update
Cash, cash equivalents and investments climbed to $349.39 million at June 30 from $108.01 million at Dec. 31, 2025.
The FDA granted RMAT designation for AlloNK with rituximab in refractory rheumatoid arthritis. A Phase 3 start is planned in the second half of 2026 in about 150 patients.
CEO Fred Aslan said EULAR data reinforced AlloNK’s potential for deep B-cell depletion, with tolerability supportive of outpatient administration.
